Extended Medicationplan for Patients with ORal Tumortherapy

Extended Medicationplan for Patients with ORal Tumortherapy - EMPORT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016498

Enrollment

Registered

2019-06-14

Start date

2018-12-19

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant neoplasms

Interventions

Group 1: Patients who are treated with an oral anticancer agent will get a standardized medication plan and the oncologic addendum for the drug taken by the patient. Additionally they receive a device

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of malignant disease, Treatment with an oral anticancer drug in the oncologic departments of the University Hospital Cologne, Age > 18 years, Sufficient knowledge of German language, Written consent

Exclusion criteria

Exclusion criteria: Mental issues or diseases which interfere with cognitive abilities (e.g. Alzheimer´s disease), Assistance through nursing service or permanent resident in a nursing home, Intention to change hospital

Design outcomes

Primary

Measure	Time frame
Feasibility by a standardized questionnaire which is developed during the pilot phase.	—

Secondary

Measure	Time frame
Adherence (Time4Med, MARS-D), Symptom burden (PRO-CTCAE)	—

Countries

Germany

Contacts

Public ContactAnna-Katharina Barnert

Universität Bonn

a.barnert@uni-bonn.de0228-734943

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026